Form 4 for OCUL OCULAR THERAPEUTIX, INC
Accepted 2022-07-15 00:00:00 ET · period of report 2022-07-01 · accession 0001104659-22-080288 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-15 | 2022-07-01 | OCUL | Ozden Rabia Gurses | Chief Medical Off | A - Grant | $0.00 | +6,667 | 52.2K | +15% | $0 |
| DM | 2022-07-15 | 2022-07-01+ | OCUL | Ozden Rabia Gurses | Chief Medical Off | A - Grant | $0.00 | +50.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-01 | A | A | 6,667 | $0.00 | 52,223 | D | — | — | (F1) On July 1, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on July 1, 2023, and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-07-14 | A | A | 10,000 | $0.00 | 10,000 | D | $4.30 · — to 2032-07-13 | 10,000 Common Stock | (F4) On July 14, 2022, the reporting person was granted an option to purchase 10,000 shares of the Company's common stock, vesting over thirty months, with 1/30 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the date of grant. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-07-01 | A | A | 20,000 | $0.00 | 40,000 | D | $18.70 · — to 2031-01-31 | 20,000 Common Stock | (F3) As previously reported, on February 1, 2021, the reporting person was granted an option to purchase 50,000 shares of the Company's common stock. The option vests in four installments based on the Company's satisfaction of certain performance criteria. The performance criteria for the first two installments were met on or prior to December 31, 2021, resulting in the vesting of the option as to 20,000 shares. The performance criteria for the third installment were not met on or prior to March 31, 2022, resulting in the termination of the option as to 10,000 shares. The option was amended by the Company and the reporting person to eliminate the performance criteria for the fourth installment, effective July 1, 2022, such that the fourth installment of the option vests over four years, with 17/48 of the shares underlying the option vesting upon July 1, 2022, and 1/48 of the shares underlying the option vesting monthly thereafter. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-07-01 | A | A | 20,000 | $0.00 | 20,000 | D | $4.09 · — to 2032-06-30 | 20,000 Common Stock | (F2) On July 1, 2022, the reporting person was granted an option to purchase 20,000 shares of the Company's common stock, vesting over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the date of grant. |